Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization
- PMID: 36251149
- DOI: 10.1111/nep.14120
Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization
Comment on
-
Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.Nephrology (Carlton). 2022 Nov;27(11):901-905. doi: 10.1111/nep.14106. Epub 2022 Sep 11. Nephrology (Carlton). 2022. PMID: 36047901
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
